Commentary

Video

Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Consuelo Bertossi, MD, assistant doctor, Division of CLL, Department of Internal Medicine III, Universitätsklinikum Ulm, discusses research further elucidating the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia (CLL), as presented at the 2024 EHA Hybrid Congress.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD